Chemical Compound Review:
AC1NUZ1E (6R,7S)-7-[[(2E)-2-(2-amino- 1,3-thiazol-4...
Synonyms:
BIDD:GT0809, ZINC03871923, AKOS015895225, 149261-27-8, Cefepime, BMY-2, ...
This record was replaced with 5464263.
- Treatment of urinary tract infections: selecting an appropriate broad-spectrum antibiotic for nosocomial infections. Sharifi, R., Geckler, R., Childs, S. Am. J. Med. (1996)
- Susceptibility of bacterial isolates to beta-lactam antibiotics from U.S. clinical trials over a 5-year period. Kessler, R.E., Fung-Tomc, J. Am. J. Med. (1996)
- Safety of cefepime: a new extended-spectrum parenteral cephalosporin. Neu, H.C. Am. J. Med. (1996)
- Antimicrobial usage and resistance trend relationships from the MYSTIC Programme in North America (1999-2001). Mutnick, A.H., Rhomberg, P.R., Sader, H.S., Jones, R.N. J. Antimicrob. Chemother. (2004)
- A new therapeutic option for the treatment of pneumonia. McCabe, R., Chirurgi, V., Farkas, S.A., Haddow, A., Heinz, G., Greene, S. Am. J. Med. (1996)
- The pharmacokinetic profile of a new generation of parenteral cephalosporin. Rybak, M. Am. J. Med. (1996)
- Effect of porins and plasmid-mediated AmpC beta-lactamases on the efficacy of beta-lactams in rat pneumonia caused by Klebsiella pneumoniae. Padilla, E., Alonso, D., Doménech-Sánchez, A., Gomez, C., Pérez, J.L., Albertí, S., Borrell, N. Antimicrob. Agents Chemother. (2006)
- Optimizing pharmacodynamic target attainment using the MYSTIC antibiogram: data collected in North America in 2002. Kuti, J.L., Nightingale, C.H., Nicolau, D.P. Antimicrob. Agents Chemother. (2004)
- Cefepime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Barradell, L.B., Bryson, H.M. Drugs (1994)
- In vitro and in vivo activities of amikacin, cefepime, amikacin plus cefepime, and imipenem against an SHV-5 extended-spectrum beta-lactamase-producing Klebsiella pneumoniae strain. Szabó, D., Máthé, A., Filetóth, Z., Anderlik, P., Rókusz, L., Rozgonyi, F. Antimicrob. Agents Chemother. (2001)
- Mutational replacement of Leu-293 in the class C Enterobacter cloacae P99 beta-lactamase confers increased MIC of cefepime. Vakulenko, S.B., Golemi, D., Geryk, B., Suvorov, M., Knox, J.R., Mobashery, S., Lerner, S.A. Antimicrob. Agents Chemother. (2002)
- Pharmacokinetics of cefepime in subjects with renal insufficiency. Barbhaiya, R.H., Knupp, C.A., Forgue, S.T., Matzke, G.R., Guay, D.R., Pittman, K.A. Clin. Pharmacol. Ther. (1990)
- Predicting evolutionary potential: in vitro evolution accurately reproduces natural evolution of the tem beta-lactamase. Barlow, M., Hall, B.G. Genetics (2002)
- Roles of beta-lactamases and porins in activities of carbapenems and cephalosporins against Klebsiella pneumoniae. Martínez-Martínez, L., Pascual, A., Hernández-Allés, S., Alvarez-Díaz, D., Suárez, A.I., Tran, J., Benedí, V.J., Jacoby, G.A. Antimicrob. Agents Chemother. (1999)
- Experimental prediction of the natural evolution of antibiotic resistance. Barlow, M., Hall, B.G. Genetics (2003)
- Uptake of cefepime by phagocytosing polymorphonuclear neutrophils and subsequent intracellular killing. Pruul, H., McDonald, P.J. Antimicrob. Agents Chemother. (1996)
- Prospective randomized comparison of cefepime and cefotaxime for treatment of bacterial meningitis in infants and children. Sáez-Llorens, X., Castaño, E., García, R., Báez, C., Pérez, M., Tejeira, F., McCracken, G.H. Antimicrob. Agents Chemother. (1995)
- In vitro activity of BMY-28142 against pediatric pathogens, including isolates from cystic fibrosis sputum. Conrad, D.A., Scribner, R.K., Weber, A.H., Marks, M.I. Antimicrob. Agents Chemother. (1985)
- Effect of a selective decontamination of the digestive tract regimen including parenteral cefepime on establishment of intestinal colonization with vancomycin-resistant Enterococcus spp. and Klebsiella pneumoniae in mice. Paterson, D.L., Stiefel, U., Donskey, C.J. Antimicrob. Agents Chemother. (2006)
- Cefepime concentrations in bronchial mucosa and serum following a single 2 gram intravenous dose. Chadha, D., Wise, R., Baldwin, D.R., Andrews, J.M., Ashby, J.P., Honeybourne, D. J. Antimicrob. Chemother. (1990)
- Extended-spectrum beta-lactamases in enterobacteriaceae in Buenos Aires, Argentina, public hospitals. Quinteros, M., Radice, M., Gardella, N., Rodriguez, M.M., Costa, N., Korbenfeld, D., Couto, E., Gutkind, G. Antimicrob. Agents Chemother. (2003)
- Influence of experimental rat model of multiple organ dysfunction on cefepime and amikacin pharmacokinetics. Mimoz, O., Jacolot, A., Padoin, C., Quillard, J., Tod, M., Louchahi, K., Samii, K., Petitjean, O. Antimicrob. Agents Chemother. (1996)
- Modulation of the intestinal flora of mice by parenteral treatment with broad-spectrum cephalosporins. van Ogtrop, M.L., Guiot, H.F., Mattie, H., van Furth, R. Antimicrob. Agents Chemother. (1991)
- Pharmacodynamics of cefepime alone and in combination with various antimicrobials against methicillin-resistant Staphylococcus aureus in an in vitro pharmacodynamic infection model. Huang, V., Rybak, M.J. Antimicrob. Agents Chemother. (2005)
- Experimental prediction of the evolution of cefepime resistance from the CMY-2 AmpC beta-lactamase. Barlow, M., Hall, B.G. Genetics (2003)
- In vitro synergy between cefepime and vancomycin against methicillin-susceptible and -resistant Staphylococcus aureus and Staphylococcus epidermidis. Lozniewski, A., Lion, C., Mory, F., Weber, M. J. Antimicrob. Chemother. (2001)
- Extension of resistance to cefepime and cefpirome associated to a six amino acid deletion in the H-10 helix of the cephalosporinase of an Enterobacter cloacae clinical isolate. Barnaud, G., Labia, R., Raskine, L., Sanson-Le Pors, M.J., Philippon, A., Arlet, G. FEMS Microbiol. Lett. (2001)
- Bacteriologic and clinical applications of a new extended-spectrum parenteral cephalosporin. Segreti, J., Levin, S. Am. J. Med. (1996)
- Pitfalls in cefepime titration from human plasma: plasma- and temperature-related drug degradation in vitro. Bugnon, D., Giannoni, E., Majcherczyk, P., Glauser, M.P., Moreillon, P. Antimicrob. Agents Chemother. (2002)
- Cefepime versus imipenem-cilastatin for treatment of nosocomial pneumonia in intensive care unit patients: a multicenter, evaluator-blind, prospective, randomized study. Zanetti, G., Bally, F., Greub, G., Garbino, J., Kinge, T., Lew, D., Romand, J.A., Bille, J., Aymon, D., Stratchounski, L., Krawczyk, L., Rubinstein, E., Schaller, M.D., Chiolero, R., Glauser, M.P., Cometta, A. Antimicrob. Agents Chemother. (2003)
- Cefepime clinical pharmacokinetics. Okamoto, M.P., Nakahiro, R.K., Chin, A., Bedikian, A. Clinical pharmacokinetics. (1993)